Abraxis BioScience Founder Awarded Ellis Island Medal of Honor.

LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ: ABBI), an integrated, global biopharmaceutical company, today announced that Patrick Soon-Shiong, M.D., founder, chairman of the board and chief executive officer of the company, was among this year's 100 recipients of the prestigious Ellis Island Medal of Honor. Honorees this year included Her Excellency Sheikha Haya Rashed Al Khalifa (President - General Assembly, United Nations), Denis A. Cortese, M.D. (President and Chief Executive Officer - Mayo Clinic), Hon. Chuck Hagel (U. S. Senator), Rep. Tom Lantos ((U.S. Congressman) and Antonio M. Perez (Chairman and Chief Executive Officer - Eastman Kodak Company). The award presentation took place at Ellis Island on May 12, 2007 and the ceremony concluded with a fireworks display at the Statue of Liberty.

Dr. Soon-Shiong, who is of Chinese heritage and a native of South Africa, is a noted research scientist, physician and surgeon, and was awarded this honor for his efforts in scientific innovation. He has devoted his career to developing next-generation technologies to enhance the medical care of patients with life-threatening diseases, including cancer, diabetes and heart disease. Dr. Soon-Shiong performed the world's first encapsulated islet transplant in a diabetic patient, developed the nanoparticle albumin bound (nab[TM]) technology platform, is a co-inventor of over 50 issued U.S. and foreign patents and has published more than 100 scientific papers.

As part of his commitment to bringing about evolutionary change to the practice of medicine and addressing the serious health care issues facing the country, Dr. Soon-Shiong and his family recently donated $35 million to the Saint John's Health Center. The donation was designed to complete the building of a world class inpatient life science center, and to begin development of a new Center for Translational Sciences.

The Ellis Island Medal of Honor, sponsored by the National Ethnic Coalition of Organizations, is presented annually to Americans who have maintained strong ties to their ancestry and furthered the growth of ethnic America. Previous honorees have been outstanding Americans who have worked in government, healthcare, industry, education, sports and entertainment. Recipients have included six United States Presidents, General Norman Schwarzkopf, Rudy Guiliani, Jay Leno, Yogi Berra, Muhammad Ali and Walter Cronkite.

About The Ellis Island Medal of Honor

Established in 1986 by NECO, the Ellis Island Medals of Honor pay tribute to the ancestry groups that comprise America's unique cultural mosaic. Held each May on Ellis Island, the event is full of pageantry, grandeur and emotion. Both Houses of Congress officially recognize the Medal of Honor, which ranks among the nation's most prestigious awards. Past Medalists include Supreme Court justices, Nobel Prize winners, American Presidents, famous athletes, entertainers, corporate giants and individuals who have inspired people, improved communities and changed lives for the better. One is presented each year to a foreign citizen for extraordinary service to the United States and the international community. For a full list of the 2007 Ellis Island Medal of Honor winners, visit www.neco.org.

About NECO

The National Ethnic Coalition of Organizations, Inc. serves as an umbrella for over 250 organizations that celebrate, educate and nurture ethnic pride, heritage, culture, tradition and commerce. NECO was created on the conviction of its founders that the diversity of the American people is what makes this nation great. Its mission is to honor and preserve this diversity and to foster tolerance, respect and understanding among religious and ethnic groups.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab[TM] platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE([R]), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.